Indications and Important Safety Informationexpand

Important Safety Information
Contraindications


IXEMPRA is contraindicated in patients:

WARNING AND PRECAUTIONS:

Toxicity in patients with hepatic impairment

Peripheral neuropathy

Myelosuppression

Hypersensitivity reactions

Cardiac adverse reactions

Pregnancy

Alcohol Content

 

Adverse reactions

Single-agent

Combination with capecitabine

Cremophor is a registered trademark of BASF AG.
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; CTC = common terminology criteria.

Indications

IXEMPRA® (ixabepilone) is indicated for treatment in combination with capecitabine for patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

IXEMPRA is indicated for treatment as a single agent for patients with metastatic or locally advanced breast cancer after failure of an anthracyclines, taxanes, and capecitabine.

Please see US Full Prescribing Information, including boxed WARNING regarding hepatic impairment.

 

Medical information

For product information or to report an adverse reaction, please call 1-844-586-8953 or e mail DrugSafety@propharmagroup.com.

This site is intended for US healthcare professionals.

The R-Pharm US Access and Support logo is a trademark and IXEMPRA® is a registered trademark of R-Pharm US Operating LLC, a wholly-owned subsidiary of R-Pharm US LLC.

© 2024, R-PHARM US. All rights reserved. IXE-00096-02   08/16